Fulgent Genetics Projects Significant 2026 Non-GAAP Loss Due to Major Customer Departure
FLGT sits 61% above its 52-week low of $14.57 on elevated volume (3.0× avg).
Summary
Fulgent Genetics reported Q4 and full-year 2025 results, but issued a significantly negative 2026 outlook, projecting a substantial non-GAAP loss due to its largest customer moving work in-house, despite positive clinical pipeline updates.
Key Events · Earnings and Guidance · FLGT
-
Q4 & FY 2025 Results
Reported Q4 revenue of $83.3 million (up 9% year-over-year) and full-year revenue of $322.7 million (up 14% year-over-year), with a GAAP loss of ($0.76) per share in Q4 and ($1.97) for the full year.
-
Negative 2026 Guidance
Projected 2026 non-GAAP loss of approximately ($1.45) per share, a significant decline from 2025's non-GAAP income of $0.42 per share.
-
Major Customer Loss
The negative 2026 outlook is primarily driven by the company's largest customer moving a significant volume of work in-house, impacting future revenue.
-
Strong Cash Position
Ended 2025 with $705.5 million in cash, cash equivalents, and marketable securities, providing financial stability and runway.
Analysis · FLGT · Industrial Applications And Services
Fulgent Genetics' latest financial report presents a mixed picture, with solid 2025 revenue growth overshadowed by a concerning 2026 outlook. The company projects a significant non-GAAP loss per share for 2026, a sharp reversal from 2025's non-GAAP income. This deterioration is primarily attributed to its largest customer internalizing a substantial volume of work, indicating a material business challenge. While the company maintains a strong cash position and reported promising preliminary Phase 2 clinical data for FID-007 in Head & Neck cancer, the near-term financial headwinds from the customer loss are substantial and will likely be a key focus for investors. The company aims for acquisitions to partially offset this impact in the second half of 2026.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.4% of the 1170 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FLGT was trading at $23.51 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $765.4M. The 52-week trading range was $14.57 to $31.04. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.